  Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 ( SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes ( T1D). The inTandem1 trial , a double-blind , 52-week phase 3 trial , randomized North American adults with T1D to placebo ( From a mean baseline of 7.57 % , placebo-adjusted HbA In a 1-year T1D study , sotagliflozin combined with optimized insulin therapy was associated with sustained HbA